PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Tim HollsteinElisabeth Steinhagen-Thiessen

Abstract

Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). We assessed the effectiveness and safety of the PCSK9i alirocumab and evolocumab in a single-center clinical practice for up to 68 weeks. In this prospective, open-label study conducted in Germany, 635 enrolled patients were treated with alirocumab [75 or 150 mg every 2 weeks (Q2W)] or evolocumab (140 mg Q2W) according to European Society of Cardiology/European Atherosclerosis Society guidelines (low-density lipoprotein cholesterol [LDL-C] > 1.81/2.59 mmol/L (70/100 mg/dL), depending on cardiovascular risk]. Investigators were able to adjust LLTs, including PCSK9i, according to their own clinical judgment. The primary effectiveness endpoint was LDL-C reduction from baseline to week 68. At baseline, approximately 50% of patients were statin intolerant, and approximately 90% reported a history of cardiovascular disease. LDL-C reductions remained generally unchanged from weeks 4 to 68 in each treatment group. At week 68, LDL-C mean percentage changes from baseline were - 41.7% (alirocumab 75 mg Q2W), - 53.7% (al...Continue Reading

References

Jun 13, 2008·Lipids in Health and Disease·Janice MayneMichel Chrétien
Apr 3, 2014·Journal of the American College of Cardiology·Michael J KorenUNKNOWN MENDEL-2 Investigators
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 18, 2015·Deutsches Ärzteblatt International·Ulrich LaufsWinfried März
Dec 22, 2015·Journal of Clinical Lipidology·Patrick M MoriartyUNKNOWN ODYSSEY ALTERNATIVE Investigators
Oct 13, 2016·The American Journal of Cardiology·Peter H JonesJennifer G Robinson
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
May 17, 2017·Journal of Clinical Lipidology·Annette M H Galema-BoersJeanine E Roeters van Lennep
Oct 11, 2017·International Journal of Clinical Practice·Monika KohliAnthony S Wierzbicki
Dec 20, 2017·Atherosclerosis·Robert M StoekenbroekG Kees Hovingh
Mar 12, 2018·Journal of Clinical Lipidology·Charles J GlueckAndrew Koren
Jul 31, 2018·Journal of Clinical Lipidology·Tiziana SampietroMascia Pianelli
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Jul 8, 2019·Drugs -- Real World Outcomes·Klaus G ParhoferW Dieter Paar
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Nov 27, 2019·European Journal of Preventive Cardiology·Francesco SbranaTiziana Sampietro

❮ Previous
Next ❯

Software Mentioned

SAS Enterprise Guide

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.